Indivior Share Discussion Threads

[dealy] 10/11/2023 08:18

incredible that it hits a 52 week low despite making huge progress

[liam1om] 10/11/2023 08:15

Down another 5% and through support here. Needs to bounce today or it could get nasty.

[ariane] 10/11/2023 06:26

Indivior swings to quarterly loss on costs despite strong sales
November 09, 2023 at 10:56 am
Share

(Alliance News) - Indivior PLC on Thursday maintained net revenue guidance, after swinging to a net loss despite seeing a sales increase in the third quarter.

For the three months ended September 30, the Virginia-headquartered pharmaceutical company reported net revenue of USD271 million, up 17% from USD232 million a year prior.

During the third quarter, US revenue rose 20% to USD227 million from USD189 million. Meanwhile, Rest of World revenue grew 2% to USD44 million from USD43 million the previous year.

By contrast, Indivior posted a net loss of USD135 million for the quarter, swung from net income of USD41 million year-on-year. Pretax loss was USD181 million, swung from profit of USD54 million.

Diluted loss per share was USD0.98, swung from earnings per share of USD0.29 a year prior.

Losses came amid higher expenses. While research and development costs were marginally lower year-on-year at USD18 million from USD20 million, selling, general and administrative expenses rose to USD390 million from USD115 million.

Earlier in October, Indivior reached an agreement to resolve claims brought by the direct purchasers in an antitrust multi-district litigation.

The litigation was centred on the claim that the pharmaceutical company stymied generic competition for the opioid addiction treatment Suboxone, in order to preserve its dominance.

Indivior agreed to pay USD385 million and book a charge of USD228 million in the third quarter, though said this would be excluded from adjusted earnings. Payment is expected to be made in November, and funded from existing cash.

"This quarter has again demonstrated the commitment and capabilities of the Indivior team. We delivered double-digit top-line performance led by strong growth of SUBLOCADE (buprenorphine extended release), which continues to shift the paradigm for the treatment of opioid use disorder," said Chief Executive Officer Mark Crossley.

"Additionally, we made good progress against our strategic priorities, with the launch of OPVEE (nalmefene) nasal spray as well as key transactions to strengthen our pipeline and to secure long-term product supply," Crossley added.

Looking ahead, the firm continues to expect full year net revenue in the range of USD1.03 billion to USD1.09 billion, reflecting growth of 18% at the mid-point compared with the previous year.

Within the total, it now expects Sublocade net revenue to be USD610 million to USD630 million, versus the previous range of USD590 million to USD630 million, based on continued strong performance in the OHS channel.

Perseris net revenue is now expected to be at the lower end of the USD45 million to USD55 million guidance range, reflecting year-to-date results and near-term competitive pressures.

Costs are expected to be higher, with selling, general and administrative expenses anticipated between USD540 million and USD550 million, from previous guidance of USD530 million to USD540 million.

Overall, Indivior continues to expect adjusted operating profit to be higher than the previous financial year's USD212 million.

Indivior shares were trading 1.8% lower at 1,511.00 pence each in London on Thursday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to [e-mail]

[steeplejack] 09/11/2023 21:03

Only closed down 5.5% on the street.

[villarich] 09/11/2023 17:53

Absolute madness. Literally the same message but with the numbers.

[youngers] 09/11/2023 16:17

I love how the company announces last month the settlement amount and the market thinks oh good that’s all sorted. Then they announce results with the same settlement in and market falls out of bed.

[casholaa] 09/11/2023 15:30

Unfortunately, I think the share price may trickle downward for a while now. That's the 'markets' for you.

[faz] 09/11/2023 15:27

THe bottom line cost for the settlement was spelt our three weeks ago, so no one should be surprised. But clearly a number of people cant do joined up thinking. It's behind them now and I see this as a buying opportunity, not a time to sell.

[gregmorg] 09/11/2023 14:15

A decent set of 3rd quarter figures and encouraging signals but headline operating losses after a whole raft of additional items, initial product launch costs and legal settlements included, sort of take any shine off. I had hoped the additional US listing would mark a new exciting chapter but that appears not to be-- for now!

[casholaa] 09/11/2023 13:12

I just got stopped out.

[youngers] 09/11/2023 10:26

Indeed, strong revenue growth continuing which can only bode well for future profitability. Looking forward to the 2024 outlook in the q4 results.

Also great to see the product diversification improving too.

[steeplejack] 09/11/2023 10:03

Results and commentary look solid.

[ariane] 09/11/2023 07:38

SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior (PRNewsfoto/Indivior)

The earnings release can be found at www.indivior.com/investors

The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link:
Participants may access the presentation telephonically by registering with the following link: [...]

[steeplejack] 23/10/2023 10:19

We can only hope that's an end to it but we all know that lawyers are always on the sniff for a remunerative case.

[gregmorg] 23/10/2023 08:59

Certainly hope its all behind us now as these episodes had become quite tedious. A long way back but in these stock market conditions I guess it's barely surprising! Seen this malaise many times before but that doesn't make it that much easier.

[youngers] 23/10/2023 08:40

Well that was expensive but great news it’s all closed now

[grupo guitarlumber] 21/8/2023 14:56

Cboe Europe - 09:55:15 2023-08-21 am EDT







1815.00 GBX +3.18%

[steeplejack] 21/8/2023 08:10

Its hard to see a time when Indivior isn't going to be susceptible to litigation from one quarter or another.There's no doubt that the company is becoming highly proficient at handling litigants,practise makes perfect i suppose.

[adrian j boris] 21/8/2023 08:03

Josh White
Sharecast News
21 Aug, 2023 07:32
Indivior settles some suboxone class action claims, Crest Nicholson lowers profit forecasts

London open

The FTSE 100 is expected to open one point lower on Monday, having closed down 0.65% on Friday at 7,262.43.

Stocks to watch

Addiction treatment specialist Indivior announced on Monday that its US division has settled claims made by the end payor class in the Suboxone antitrust litigation. The FTSE 250 company said it expected to pay $30m, which would be deducted from a reserved $188m for the litigation. Meanwhile, Indivior US was preparing for a 30 October trial related to other claims, but remained open to a settlement there as well.

[youngers] 21/8/2023 07:51

2 down 1 to go

[adrian j boris] 21/8/2023 07:12

21 August 2023

FOR IMMEDIATE RELEASE

Indivior Reaches Agreement with End Payor Class

to Resolve Their Antitrust Multi-District Litigation Claims

Richmond, VA, August 21, 2023 - Indivior PLC (LSE/Nasdaq: INDV) , a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL"). The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL. The Agreement is subject to initial approval by the United States District Court for the Eastern District of Pennsylvania (the "Court"), a notice period, participation by an appropriate number of end payors and final approval of the Court.

As part of the Agreement, the Company expects to pay $30 million to the End Payor Claimants. The settlement amount is in line with the current provision of $188 million for the MDL. Once the Agreement is approved and entered by the Court, the final settlement amount will be recorded against the $188 million provision. Payment into an escrow account for the benefit of the End Payor Claimants is expected to be made in September of 2023, and funded from the Company's existing cash balance.

"We remain focused on helping those suffering from substance use disorders and mental illness," said Mark Crossley, Chief Executive Officer. "Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders."

As set out in the Company's half year report on July 27, 2023, the Company continues to prepare for trial on October 30, 2023, in relation to the remaining claims of the direct purchaser class while at the same time exploring the possibility of settlement at the right value with this class.

[gregmorg] 27/7/2023 14:38

The webcast covered the potential litigation statement reasonably comfortably I thought with the cloud looking far less dangerous than I first feared.

Still think Cloud needs removing by October before court proceedings start although company has settled all the other 41-42 cases well within its original $290m provision (of which $187.5m provision remains), in fact the 41-42 litigants settled for $102.5m. Hopefully ,the remaining 2 litigants settle within the company's corporate criteria within a timescale and we move on. Momentum on other fronts appears very encouraging. but no idea as to what the US will make of it!